Formed in June 2009, RealBio® Technology, Inc. is a premier life sciences product development company dedicated to the development and commercialization of BioRealistic Cell and Tissue Culture technology to enhance life sciences research.
With a focus on cell and tissue technology, RealBio® has developed, the RealBio D4 ™ Culture System, a system demonstrating significant improvements and promise beyond current cell culture technology.
President and CEO
With a background in management, sales, and finance, Paul has served in a variety of leadership roles at industry leaders Gillette CANADA, Inc., G.D.Searle (a division of Monsanto), The NutraSweet Company (a division of Monsanto), and Pharmacia (purchased by Pfizer in 2003).
Most recently, Paul was the Executive in Residence for the SWMF Life Science Fund, a private for-profit $50 Million venture fund supported by Southwest Michigan First (SWMF), a private non-profit encouraging economic growth, job creation, and entrepreneurship in the southwest Michigan region.
Paul holds a Masters in Management from the JL Kellogg Graduate School of Management at Northwestern University and a Honors Bachelor of Commerce from McMaster University in Hamilton, Ontario, Canada.
Director, Technology
Lee is the co-founder and past CEO/President/Chairman of BioFlow Technology, Inc., a life science company developing and marketing 3D culture system tools. Previously Lee held positions at Corning Inc., Charles River, New View VIP, and Aastrom Biosciences, Inc., and has extensive experience in management, quality assurance, and technical services. Lee holds a Bachelor of Science from Michigan State University.
To contact Lee call (269) 544-1088 or email him at lee@realbiotechnology.com.
Vice President, Product Development
Bill brings more than 25 years of experience in the pharmaceutical and life science industry to his position at RealBio®. During more than 18 years at Upjohn/Pharmacia/Pfizer, he was responsible for activities spanning the entire drug development continuum including development and validation of cell-based assays supporting the discovery and quality control of biopharmaceuticals. More recently, Bill worked in a contract research organization where he served as Director of immunoassay and biomarker services, Manager of GMP product testing, and Director of Business Development. Bill holds a B.S. (Biology) from the State University of New York, College at Oswego and a M.S. (Microbiology) from The Ohio State University. Bill also received specialized cell and tissue culture training from the W. Alton Jones Cell Science Center in Lake Placid, New York.
To contact Bill call (269) 544-3013 or email him at wpfund@realbiotechnology.com.
Managing Director, Southwest Michgian First (SWMF) Life Science Fund
Pat Morand is Managing Director of the SWMF Life Science Fund, headquartered in Kalamazoo, Michigan. The SWMF Life Science Fund is the nation's only community-based venture fund.
With $100 million under management, Pat is responsible for sourcing all potential investments, leading them through the fund’s stringent due diligence process and overseeing the fund’s portfolio company management teams. Prior to joining the fund, Pat was a three-time Chief Executive Officer in the biologics industry; Vice President of Commercial Operations for Genesis Therapeutics; Executive Vice President of Sequitor Medical Technologies; and Executive in Residence of the Pittsburgh Life Sciences Greenhouse, a public/private investor in regional life sciences companies where he provided executive support to over 65 companies, representing $100M of investment and 121 employees.
Pat is a graduate of The Athenaeum of Ohio with a Bachelor of Arts Degree in Philosophy.
Mr. Ball has a long and proven record for bringing life science products to market and capitalizing on existing product potential. He is currently Chief Commercial Officer at Accuri Cytometers where he developed a novel commercialization model that is highly capital efficient. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, a venture backed technology start-up developing high-end imaging flow cytometers. He has also served as Chief Commercial Officer for Molecular Probes, Inc., the world leader in reagents for cell analysis, including flow cytometry consumables. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America.
President and CEO RealBio® Technology, Inc.
Managing Director, Fjord Ventures
Roy’s experience includes 32 years with Johnson and Johnson. He was Vice President of New Product Development at Janssen Pharmaceutical where he launched Risperdal and Reminly. Roy was also a Vice President with the Johnson & Johnson Development Corp., the venture capital arm of J&J where he invested in 19 companies and held 11 board of director seats. At J&J, Roy also built a virtual R&D capability for the J&J Pharmaceutical organization.
George Dunbar joined Arboretum Ventures in 2010 as a Venture Partner. George utilizes his extensive healthcare operating experience as the former CEO of a number of public and private venture-backed healthcare companies to evaluate new investment opportunities in the diagnostics, life sciences tools and medical devices sectors. George currently serves as the Chairman of Arboretum portfolio company Accuri Cytometers and Director with CerviLenz and Life Magnetics.
Prior to joining Arboretum Ventures, George was most recently the President, CEO and Chairman of Aastrom Biosciences, a publicly-traded, clinical development stage healthcare company based in Ann Arbor. Prior to Aastrom, Mr. Dunbar worked with several national venture capital firms, serving as the CEO of a number of early-stage life sciences companies, including Quantum Dot (acquired by Invitrogen) and Epic Therapeutics (acquired by Baxter Healthcare). He has also held senior positions in licensing, business development and marketing with The Ares-Serono Group and Amersham International, now GE Healthcare.
George is a graduate of Auburn University, holding both a Master’s degree in Business Administration and an undergraduate degree in Electrical Engineering, and currently sits on the MBA Advisory Board of the College of Business at Auburn.
Jerry Culp has a 25 year history of leading the conceptualization, development and commercialization of many high tech product platforms. For the past 19 years Jerry has been with the Stryker Corporation and currently serves as Vice President, Global Development where he is responsible for team and technology architectures required to ensure Stryker’s leadership in future medical markets. Previously Jerry served as Vice President, Research and Development at Stryker’s Instruments Division where he delivered numerous commercially successful product platforms to the market. Before his tenure at Stryker, Jerry was with Radian Research where he served as Director, Research and Development. Radian Research is a world leader in providing metrology level calibration equipment to the electric utility industry. Jerry is an electrical engineer by training and has a BS from Purdue University.